1 published article · Updated continuously
6 trials tracked for chronic inflammatory demyelinating polyneuropathy: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 271 citations.
Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Clinical trials for inflammatory neuropathies demonstrate significant improvements in mobility and strength using specific immunoglobulin treatments. One study showed that IgPro20 (low dose) resulted in a statistically significant reduction in the percentage of subjects experiencing CIDP relapse or withdrawal during subcutaneous treatment (p=0.007). Additionally, this intervention showed no significant change in INCAT scores (p=0.005) and a measurable decrease in mean grip strength decline compared to other groups (p=0.004).
Another study utilizing a 10% liquid formulation of human immunoglobulin demonstrated consistent improvements in Adjusted INCAT Scores across multiple measurement points.
AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
